---
title: "Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | SNTI Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286418645.md"
description: "Senti Biosciences Holdings has announced a positive outcome from its FDA RMAT meeting regarding the registrational clinical and CMC strategy for SENTI-202, aimed at treating relapsed/refractory AML. The company also provided significant updates on the efficacy and durability of the SENTI-202 clinical program."
datetime: "2026-05-14T04:40:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286418645.md)
  - [en](https://longbridge.com/en/news/286418645.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286418645.md)
generator: "portal-rs"
---

# Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | SNTI Stock News

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | SNTI Stock News

### Related Stocks

- [SNTI.US](https://longbridge.com/en/quote/SNTI.US.md)

## Related News & Research

- [Moleculin highlights interim data from pivotal MIRACLE Phase 2/3 Annamycin trial in relapsed/refractory AML](https://longbridge.com/en/news/297191000.md)
- [Oryzon Genomics wins US notice of allowance for iadademstat-gilteritinib AML patent application](https://longbridge.com/en/news/297475261.md)
- [Can Komzifti's Early Adoption Support Kura Oncology's Next Phase Of Growth?](https://longbridge.com/en/news/296928079.md)
- [PMV Pharma says rezatapopt posts 46% response rate in Phase 2 platinum-resistant ovarian cancer trial](https://longbridge.com/en/news/297555827.md)
- [Mira Pharmaceuticals reports positive 7-day rat, dog tox studies for oral pain drug MIRA-55 ahead of IND push](https://longbridge.com/en/news/297649032.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**